In this instalment of Health Innovators, Paul Tunnah, Healthware’s chief content officer, sits down with Dr Anthony Yanni, senior vice president and global head of patient centricity at Ast
Astellas has won a reprieve in its attempt to stop Pfizer's generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a
Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-
The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women and minority communities in their businesses, but are they meeting
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic ex
Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients who don't respond t